XML 54 R32.htm IDEA: XBRL DOCUMENT v3.20.4
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2020
Income Taxes [Abstract]  
(Loss) Income from Continuing Operations Before Income Taxes

Loss before income taxes consisted of the following components:

 

 

 

 

 

 

 

 

 

Year Ended December 31, 

 

    

2020

    

2019

United States

 

$

(21,583,000)

 

$

(18,341,000)

Foreign

 

 

(598,000)

 

 

(1,138,000)

Total

 

$

(22,181,000)

 

$

(19,479,000)

 

Reconciliation of Statutory to Effective Tax Rates

The differences between the Company’s effective tax rate and the U.S. federal statutory tax rate were as follows:

 

 

 

 

 

 

 

 

December 31, 

 

 

    

2020

    

2019

 

U.S. federal statutory income tax rate

 

21.0

%  

21.0

%

Adjustments for tax effects of:

 

 

 

 

 

State income taxes, net of federal tax

 

6.6

%  

2.6

%

Stock-based compensation

 

(0.7)

%  

(0.5)

%

Change in valuation allowance

 

(28.5)

%  

(22.7)

%

Net operating loss carryforwards and credit expirations

 

 0

%  

(3.1)

%

Stock issuance costs

 

 0

%  

(1.2)

%

Gain on derivative liability extinguishment

 

 0

%  

1.2

%

Slovenia facility sale

 

 0

%  

1.9

%

Permanent differences

 

 0

%  

1.3

%

Other

 

1.6

%

(0.5)

%

Effective income tax rate

 

0.0

%  

0.0

%

 

Components of Deferred Tax Assets

Significant components of the Company’s deferred tax assets and liabilities were as follows:

 

 

 

 

 

 

 

 

 

December 31, 

 

    

2020

    

2019

Deferred tax assets:

 

 

 

 

 

 

Net operating loss carryforwards

 

$

31,243,000

 

$

26,291,000

Capitalized research and development

 

 

15,789,000

 

 

15,262,000

Stock-based compensation

 

 

2,087,000

 

 

1,358,000

Depreciation and amortization

 

 

1,405,000

 

 

1,632,000

Lease accounting

 

 

3,478,000

 

 

801,000

Other

 

 

989,000

 

 

981,000

Total deferred tax assets before valuation allowance

 

 

54,991,000

 

 

46,325,000

Less: valuation allowance

 

 

(51,972,000)

 

 

(45,670,000)

Total deferred tax assets after valuation allowance

 

 

3,019,000

 

 

655,000

 

 

 

 

 

 

 

Deferred tax liabilities:

 

 

  

 

 

  

Right-of-use asset

 

 

(3,019,000)

 

 

(655,000)

In-process research and development

 

 

(3,077,000)

 

 

(3,077,000)

Total deferred tax liabilities

 

 

(6,096,000)

 

 

(3,732,000)

Net deferred tax liability

 

$

(3,077,000)

 

$

(3,077,000)